Four-year research collaboration combines Pfizer’s deep experience in global drug development, including programs utilizing messenger RNA (mRNA), lipid nanoparticles (LNP), and gene therapy, with Beam’s leadership in base editing and mRNA/LNP delivery technologies
Despite the challenges of pandemic disruptions, drug developers advance promising therapies for conditions, including Alzheimer's, diabetes and asthma
The transaction is expected to close in the first quarter of 2022
Partnering to build biosynthesis processes and a pharmaceutical production platform
A toll-free helpline to be set up to help doctors and patients
The product is expected to be available in a week’s time
The company will market it under the brand name Molflu
Systemic Lupus Erythematosus, or Lupus, is an autoimmune chronic inflammatory disease. The prevalence of SLE in the U.S. has been reported to be between 20 to 150 cases per 100,000. In India, the reported prevalence of SLE is 3.2 per 100,000
The investment in Yapan Bio allows Piramal Pharma Solutions to broaden its service offerings in the fast-growing biologics CDMO space
Since its launch, the medical devices park in Sultanpur has received overwhelming response with more than 50 companies lining up to set up their manufacturing or research and development units
Subscribe To Our Newsletter & Stay Updated
